Last Updated: November 16, 2026

Investigational Drug Information for INCB054707

« Back to Dashboard


What is the development status for investigational drug INCB054707?

INCB054707 is an investigational drug.

There have been 13 clinical trials for INCB054707. The most recent clinical trial was a Phase 2 trial, which was initiated on December 14th 2022.

The most common disease conditions in clinical trials are Hidradenitis Suppurativa, Hidradenitis, and Vitiligo. The leading clinical trial sponsors are Incyte Corporation, Incyte Biosciences Japan GK, and [disabled in preview].

There are fifty-four US patents protecting this investigational drug and two hundred and thirteen international patents.

Recent Clinical Trials for INCB054707
TitleSponsorPhase
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Incyte CorporationPhase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Incyte CorporationPhase 3
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentIncyte CorporationPhase 1

See all INCB054707 clinical trials

Clinical Trial Summary for INCB054707

Top disease conditions for INCB054707
Top clinical trial sponsors for INCB054707

See all INCB054707 clinical trials

US Patents for INCB054707

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB054707 ⤷  Start Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB054707 ⤷  Start Trial Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB054707 ⤷  Start Trial Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB054707 ⤷  Start Trial Heterocyclic compounds as PI3K-.gamma. inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB054707 ⤷  Start Trial Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB054707 ⤷  Start Trial Crystalline forms of a PI3K inhibitor Incyte Corporation (Wilmington, DE) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INCB054707

Drugname Country Document Number Estimated Expiration Related US Patent
INCB054707 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Start Trial
INCB054707 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26 ⤷  Start Trial
INCB054707 Australia AU2015244044 2034-04-08 ⤷  Start Trial
INCB054707 Australia AU2020213313 2034-04-08 ⤷  Start Trial
INCB054707 Australia AU2022206693 2034-04-08 ⤷  Start Trial
INCB054707 Brazil BR112016023322 2034-04-08 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

INCB054707 (Povorcitinib) Development Update and Market Projection

Last updated: October 11, 2026

INCB054707, now known as povorcitinib, is Incyte’s oral, selective Janus kinase 1 (JAK1) inhibitor. The lead commercial opportunity is moderate-to-severe hidradenitis suppurativa (HS), followed by nonsegmental vitiligo and other inflammatory diseases. As of mid-2024, povorcitinib remained investigational, with no FDA approval, Orange Book listing, or commercial revenue. Its value depends on Phase 3 efficacy, long-term JAK1 safety, and the ability to compete with approved biologics and topical therapies.

What is INCB054707 and how does povorcitinib work?

Povorcitinib is an oral small-molecule JAK1 inhibitor designed to suppress signaling from cytokines involved in inflammatory and autoimmune diseases. The compound was previously identified by its development code, INCB054707.

The principal target indications are:

Indication Development status through mid-2024 Commercial rationale
Hidradenitis suppurativa Phase 3 Large unmet need and limited systemic treatment options
Nonsegmental vitiligo Phase 2, with further development planned No widely adopted oral standard of care
Asthma Early-to-mid-stage clinical development Potential biomarker-selected opportunity
Prurigo nodularis and other inflammatory disorders Earlier-stage or exploratory Optionality, but limited visibility

Povorcitinib differs from topical ritlecitinib and ruxolitinib because it is designed for systemic oral administration. That route could support treatment of extensive disease but also creates greater regulatory scrutiny around infections, thrombosis, cardiovascular events, malignancy, and laboratory abnormalities associated with the JAK inhibitor class.

What is the latest development status of povorcitinib?

The most advanced program is HS. Incyte has reported positive mid-stage data and advanced the compound into Phase 3 studies known as STOP-HS1 and STOP-HS2. These trials evaluate oral povorcitinib against placebo in adults with moderate-to-severe HS, with Hidradenitis Suppurativa Clinical Response (HiSCR) as a central efficacy measure (Incyte Corporation, 2023a; ClinicalTrials.gov, n.d.-a).

The development update is:

Milestone Status
Discovery and early clinical development Completed
HS Phase 2 studies Positive company-reported results
HS Phase 3 studies Ongoing through mid-2024
Vitiligo Phase 2 development Positive proof-of-concept data reported
FDA approval None
NDA submission None publicly reported
Commercial launch None
Revenue None

Incyte has also evaluated povorcitinib in nonsegmental vitiligo. The therapeutic thesis is that systemic JAK1 inhibition may affect inflammatory pathways linked to melanocyte destruction. The program’s commercial potential is greater if povorcitinib can produce clinically meaningful facial and total-body repigmentation without the treatment burden associated with topical therapy (Incyte Corporation, 2023b).

What clinical data support povorcitinib in hidradenitis suppurativa?

Phase 2 HS data indicated dose-related clinical activity, including improvements in HiSCR response and inflammatory disease measures. The evidence was sufficient for Incyte to initiate Phase 3 testing, but the Phase 2 data do not establish registration-level efficacy or long-term safety.

The main clinical questions for the Phase 3 program are:

  1. Whether povorcitinib can achieve a durable HiSCR50 response against placebo.
  2. Whether it improves abscesses, draining tunnels, pain, and quality of life.
  3. Whether its benefit remains competitive with secukinumab and bimekizumab.
  4. Whether an oral JAK1 safety profile is acceptable for chronic HS treatment.
  5. Whether dosing can be maintained without clinically meaningful laboratory toxicity.

HS is a chronic disease requiring repeated treatment. A short-term response may not be sufficient for approval or broad payer coverage if relapse occurs rapidly after discontinuation.

When could povorcitinib reach the market?

A favorable HS development path could support regulatory filings after completion of the Phase 3 program and required follow-up. A realistic commercial timing framework is:

Event Base-case timing
Completion of pivotal HS data collection 2025-2026
Potential FDA filing 2026-2027
Potential FDA decision 2027-2028
Earliest broad U.S. commercial availability 2027-2028
Vitiligo filing, if successful 2028 or later

These dates are scenario estimates, not disclosed regulatory commitments. Delays could result from enrollment, safety follow-up, manufacturing validation, or a requirement for additional studies.

What is the FDA and Orange Book status of INCB054707?

Povorcitinib was not FDA-approved as of mid-2024. It therefore had:

  • No approved label.
  • No FDA-recognized indication.
  • No New Drug Application approval.
  • No Orange Book-listed drug product.
  • No FDA-approved exclusivity period.
  • No commercial reference product against which an ANDA applicant could file a Paragraph IV certification.

Because the compound is a small molecule, the likely U.S. follow-on pathway would be an abbreviated new drug application after applicable patents and regulatory exclusivities expire. A biosimilar pathway does not apply.

What patents protect povorcitinib?

Povorcitinib’s protection is expected to depend on a combination of:

  • Composition-of-matter patents covering the active molecule.
  • Pharmaceutical-composition patents.
  • Treatment-method patents for HS, vitiligo, and other inflammatory diseases.
  • Formulation and dosage-regimen patents.
  • Manufacturing and process patents.

No Orange Book patent expiration date existed as of mid-2024 because the product had not been approved. Public patent-family information can indicate potential protection into the late 2030s, but the commercial exclusivity date will depend on the claims that survive prosecution, post-grant review, litigation, patent-term adjustment, patent-term extension, and any terminal disclaimers.

The most valuable claims are likely composition-of-matter claims. Method-of-use claims may extend the commercial life of particular indications, but they are easier to challenge and may not block all generic prescriptions if a generic launches with a permitted skinny label.

What formulations are protected by povorcitinib patents?

The development program centers on oral systemic dosing. Relevant formulation protection may cover:

  • Immediate-release oral tablets or capsules.
  • Specific dose strengths.
  • Solid-state forms and salts.
  • Stability-enhancing excipients.
  • Once-daily administration.
  • Disease-specific dose regimens.

Formulation patents would have less value than a valid composition-of-matter patent if a competitor can develop a non-infringing formulation. Manufacturing patents may raise technical barriers but generally provide narrower protection.

Are there Paragraph IV challenges or patent litigation involving povorcitinib?

No public Paragraph IV challenge or major U.S. patent litigation involving povorcitinib was identified through mid-2024. That result is consistent with the compound’s pre-approval status.

Potential future disputes could involve:

  • Generic challenges to composition-of-matter patents.
  • Method-of-use patents for HS or vitiligo.
  • Patent-term-extension calculations.
  • Written-description and enablement challenges.
  • Obviousness challenges based on earlier JAK1 inhibitor disclosures.
  • Skinny-label disputes involving unclaimed indications.

The highest litigation risk would arise after FDA approval and publication of Orange Book-listed patents. Before approval, patent disputes are more likely to involve licensing, inter partes review, or challenges by development-stage competitors than an ANDA Paragraph IV case.

Which companies challenge povorcitinib commercially?

Povorcitinib would enter two different competitive markets.

Hidradenitis suppurativa competitors

Product Sponsor Modality Regulatory position
Humira AbbVie Anti-TNF biologic Approved for HS; biosimilar competition
Cosentyx Novartis IL-17A antibody Approved for adult HS
Bimzelx UCB IL-17A/IL-17F antibody Approved in the U.S. for adult HS in 2024
Remicade and infliximab products Johnson & Johnson and others Anti-TNF biologic Off-label or institutionally used in some HS settings
Investigational oral and biologic agents Multiple companies Various mechanisms Pipeline competition

Povorcitinib’s differentiator would be oral dosing. Its disadvantages would include the systemic safety concerns associated with JAK inhibition and the absence of long-term outcomes at launch.

Vitiligo competitors

Product Sponsor Modality Regulatory position
Opzelura Incyte Topical ruxolitinib cream FDA-approved for nonsegmental vitiligo in patients aged 12 and older
Litfulo Pfizer Oral JAK3/TEC-family inhibitor Approved for severe alopecia areata, not vitiligo
Phototherapy Multiple providers Non-drug treatment Established treatment option
Investigational oral agents Various companies JAK, TYK2, and immune pathways Development-stage

Incyte’s ownership of both Opzelura and povorcitinib could support portfolio positioning in vitiligo. It could also create internal channel and reimbursement tradeoffs if an oral product displaces the company’s topical product in some patients.

How strong is the povorcitinib patent and regulatory estate?

The estate is strategically promising but not yet commercially validated.

Factor Assessment
Composition-of-matter protection Potentially strong if claims remain broad and valid
Regulatory exclusivity None before approval
Orange Book position None before approval
Formulation protection Likely secondary to molecule claims
Method-of-use protection Potentially important for HS and vitiligo
Generic challenge timing Not meaningful until approval and patent listing
Biosimilar risk Not applicable
Manufacturing barrier Moderate, subject to process complexity and supply scale
Litigation exposure Low before approval; increases after filing and listing

The primary risk is clinical rather than legal. A strong patent estate cannot offset an inadequate Phase 3 benefit-risk profile.

What is the market size and revenue projection for povorcitinib?

Povorcitinib’s commercial market depends heavily on its first approved indication.

Hidradenitis suppurativa scenario

The U.S. HS market includes patients with moderate-to-severe disease who receive biologics, immunosuppressants, antibiotics, surgery, or no sustained systemic therapy. An oral agent could expand treatment earlier in the disease course if payers accept its efficacy and safety.

A scenario-based peak-sales range is:

Scenario Key assumptions Estimated global peak sales
Downside Narrow label, safety restrictions, strong biologic competition $250 million-$600 million
Base case U.S. HS approval, durable efficacy, selective international launches $800 million-$1.5 billion
Upside HS plus vitiligo approval, broad payer access, strong oral preference $2 billion-$3 billion

These estimates are analytical projections, not Incyte guidance. The base case assumes a net price below many specialty biologics, meaningful U.S. uptake, and use in patients who prefer oral treatment or have inadequate biologic responses.

Vitiligo contribution

Vitiligo could add $300 million-$1 billion in peak annual sales if povorcitinib demonstrates meaningful whole-body repigmentation and avoids a boxed-warning-driven prescribing limitation. The opportunity is smaller if clinicians use oral treatment only after failure of topical ruxolitinib and phototherapy.

The combined opportunity is most sensitive to:

  • HiSCR50 and HiSCR75 response rates.
  • Duration of response.
  • Long-term cardiovascular and thrombotic safety.
  • The FDA label’s age and disease-severity restrictions.
  • Payer step therapy against Humira, Cosentyx, Bimzelx, or Opzelura.
  • International reimbursement.
  • Competitive oral JAK or TYK2 programs.

What generic launch risks exist for povorcitinib?

A generic launch is unlikely before the expiry or invalidation of enforceable composition-of-matter and formulation patents. The most plausible launch pathways are:

  1. A full-label generic after all relevant patents expire.
  2. A skinny-label generic targeting unprotected indications.
  3. A settlement-based launch before patent expiry.
  4. A court decision invalidating a key patent.
  5. A competing oral anti-inflammatory product that erodes share without directly copying povorcitinib.

The risk profile will become clearer only after approval, Orange Book listing, patent-term calculations, and disclosure of the final dosage form.

What licensing deals and settlements involve povorcitinib?

Povorcitinib has been developed by Incyte. No major third-party licensing transaction or publicly disclosed patent settlement involving povorcitinib was identified through mid-2024. Incyte retains control over the principal development and commercialization strategy.

Key Takeaways

  • INCB054707 is povorcitinib, an oral selective JAK1 inhibitor owned and developed by Incyte.
  • Hidradenitis suppurativa is the lead indication and the main value driver.
  • Phase 3 HS studies were ongoing through mid-2024.
  • Vitiligo is the second major opportunity, supported by Phase 2 data.
  • Povorcitinib had no FDA approval, Orange Book listing, Paragraph IV challenge, or commercial revenue as of mid-2024.
  • A plausible combined peak-sales range is $800 million-$3 billion, depending on HS and vitiligo outcomes.
  • The principal risks are Phase 3 efficacy, JAK-class safety, payer restrictions, and competition from Cosentyx, Bimzelx, Humira, and Opzelura.
  • Patent value is likely highest in composition-of-matter claims, but exact commercial expiry depends on prosecution and future Orange Book listings.

FAQs About INCB054707 and Povorcitinib

Is INCB054707 the same drug as povorcitinib?

Yes. INCB054707 is the development code for povorcitinib, Incyte’s oral selective JAK1 inhibitor.

Is povorcitinib approved for hidradenitis suppurativa?

No. Povorcitinib remained investigational and had not received FDA approval for HS as of mid-2024.

Can povorcitinib compete with Cosentyx and Bimzelx?

Yes, if approved. Its principal differentiation would be oral administration rather than biologic injection. Its competitive position will depend on Phase 3 efficacy, safety, durability, and payer access.

Does povorcitinib have biosimilar risk?

No. Povorcitinib is a small molecule, so future competition would come primarily from generic drug applicants rather than biosimilar developers.

What is the largest commercial risk for povorcitinib?

The largest risk is failure to demonstrate a sufficiently favorable long-term benefit-risk profile for chronic inflammatory disease treatment. JAK-class safety findings could restrict use even if efficacy is positive.

References

ClinicalTrials.gov. (n.d.-a). Study of povorcitinib in participants with moderate-to-severe hidradenitis suppurativa. U.S. National Library of Medicine. https://clinicaltrials.gov/

Incyte Corporation. (2023a). Incyte announces initiation of Phase 3 STOP-HS studies of povorcitinib in hidradenitis suppurativa. Incyte investor and corporate communications.

Incyte Corporation. (2023b). Incyte presents positive Phase 2 data for povorcitinib in nonsegmental vitiligo. Incyte investor and corporate communications.

U.S. Food and Drug Administration. (2022). FDA approves first topical treatment for vitiligo. https://www.fda.gov/

U.S. Food and Drug Administration. (2024). Bimzelx approval for moderate-to-severe hidradenitis suppurativa. https://www.fda.gov/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.